ArticleScientific reports2026
Letermovir prophylaxis and early CMV DNAemia after allogeneic hematopoietic stem cell transplantation: a real‑world study from China.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Letermovir is a cytomegalovirus (CMV) prophylactic agent that is not associated with clinically significant myelosuppression. However, real-world data regarding its clinical use in Chinese allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain limited. This study aimed to assess CMV DNAemia during letermovir prophylaxis and its associations with other viral infections and clinical outcomes. We conducted a single-arm retrospective study of consecutive allo-HSCT recipients treated between July 2022 and December 2023 at the First Affiliated Hospital of Xi'an Jiaotong University. Patients who received letermovir within 28 days post-transplant were analyzed. The primary endpoint was the 100-day cumulative incidence of CMV DNAemia. Secondary endpoints included CMV end‑organ disease, acute graft‑versus‑host disease (aGVHD), other viral infections, and survival outcomes. Among 74 allo-HSCT recipients receiving letermovir prophylaxis, the 100‑day cumulative incidence of CMV DNAemia was 18.9% (95% CI, 10-28%), which remained similar after exclusion of CMV serostatus donor‑negative/recipient‑positive(D-/R+) cases (19.4%). The 100‑day cumulative incidence of aGVHD was 17.6%. In competing‑risk analyses treating death as a competing event, time‑dependent associations were observed between CMV DNAemia and aGVHD. Lower letermovir exposure (p = 0.036), delayed initiation of prophylaxis(p = 0.041), and use of high‑dose corticosteroids (p = 0.020) were more frequently observed among patients with breakthrough CMV DNAemia. This real‑world study describes the incidence and clinical characteristics of early CMV DNAemia in allo‑HSCT recipients receiving letermovir prophylaxis. Lower letermovir exposure and the use of high‑dose corticosteroids were more commonly observed among patients with breakthrough CMV DNAemia, highlighting clinical factors that warrant attention in this setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.